on TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma Increases Allocated Resources for Liquidity Contract
TME Pharma N.V., a Berlin-based clinical-stage biotechnology company, announced the increase in resources allocated to its liquidity contract with Invest Securities. This decision follows the closure of an account as part of an internal optimization process, contributing 349 treasury shares.
This move aligns with article 4 of the AMF Decision no. 2021-01, aiming to bolster the cash balance and securities resources of the liquidity account.
As of August 12, 2024, post-market close, the liquidity contract now includes 76,562 shares and a cash balance of €7,255.53. This is a significant increase from the half-year report of June 30, 2024, which noted 63,403 shares and a cash balance of €8,943.42.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TME PHARMA N.V. news